PTEN and neoplasm: Trastuzumab-resistant BC cells were reported to increase NOTCH1 expression, which represses phosphatase and tensin homolog (PTEN) levels, resulting in the activation of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 (MAPK/ERK1/2) and contributing to maintaining BCSCs survival and tumor-initiating potential [60].